MX2017011607A - Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas. - Google Patents
Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas.Info
- Publication number
- MX2017011607A MX2017011607A MX2017011607A MX2017011607A MX2017011607A MX 2017011607 A MX2017011607 A MX 2017011607A MX 2017011607 A MX2017011607 A MX 2017011607A MX 2017011607 A MX2017011607 A MX 2017011607A MX 2017011607 A MX2017011607 A MX 2017011607A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- pharmaceutical composition
- line
- type
- active agents
- Prior art date
Links
- NTTQCLSBWRKUIJ-UHFFFAOYSA-N 2,3-dihydroimidazo[1,2-c]quinazoline Chemical class C1=CC=C2C3=NCCN3C=NC2=C1 NTTQCLSBWRKUIJ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000013543 active substance Substances 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 206010014733 Endometrial cancer Diseases 0.000 abstract 2
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 2
- 201000009273 Endometriosis Diseases 0.000 abstract 2
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 abstract 2
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 abstract 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 abstract 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- -1 2,3-dihydroimidazo[1,2-c]quinazoline compound Chemical class 0.000 abstract 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 abstract 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 abstract 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 abstract 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 abstract 1
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 abstract 1
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 abstract 1
- 101001098116 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit gamma Proteins 0.000 abstract 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 abstract 1
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 abstract 1
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 abstract 1
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 abstract 1
- 101000692672 Homo sapiens Phosphoinositide 3-kinase regulatory subunit 4 Proteins 0.000 abstract 1
- 101000692678 Homo sapiens Phosphoinositide 3-kinase regulatory subunit 5 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 abstract 1
- 102100026177 Phosphatidylinositol 3-kinase regulatory subunit beta Human genes 0.000 abstract 1
- 102100037553 Phosphatidylinositol 3-kinase regulatory subunit gamma Human genes 0.000 abstract 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 abstract 1
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 abstract 1
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 abstract 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 abstract 1
- 102100026481 Phosphoinositide 3-kinase regulatory subunit 4 Human genes 0.000 abstract 1
- 102100026478 Phosphoinositide 3-kinase regulatory subunit 5 Human genes 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Epoxy Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La presente invención se refiere a: - uso de un compuesto de 2,3-dihidroimidazo[1,2-c]quinazolina o de una composición farmacéutica que lo contiene, como un único agente activo o de una combinación de a) dicho compuesto o una composición farmacéutica que contiene dicho compuesto y b) uno o varios otros agentes activos, para la preparación de un medicamento para el tratamiento o la prevención de cáncer de endometrio (de ahora en más en la presente, abreviado como "EC"), en particular EC de primera línea, de segunda línea, recurrente, refractario, de tipo I o de tipo II o endometriosis; - combinaciones de a) dicho compuesto y b) uno o varios otros agentes activos; - una composición farmacéutica que comprende dicho compuesto como un único agente activo para el tratamiento de cáncer de endometrio (de ahora en más en la presente, abreviado como "EC"), en particular EC de primera línea, de segunda línea, recurrente, refractario, de tipo I o de tipo II o endometriosis; - una composición farmacéutica que comprende una combinación de a) dicho compuesto y b) uno o varios otros agentes activos; - uso de biomarcadores que es la pérdida de supresor tumoral PTEN o FBXW7, para predecir la sensibilidad y/o la resistencia de un paciente con cáncer a dicho compuesto y suministro de una dosis racional para incrementar la sensibilidad y/o para superar la resistancia; - un método de determinación de la pérdida de supresor tumoral PTEN o FBXW7; y - un método de determinación de perturbaciones en PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 y/o FGFR4; pérdida y alteración de PTEN de PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 y/o FGFR4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130547P | 2015-03-09 | 2015-03-09 | |
| PCT/EP2016/054728 WO2016142313A1 (en) | 2015-03-09 | 2016-03-07 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011607A true MX2017011607A (es) | 2018-04-10 |
Family
ID=55484986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011607A MX2017011607A (es) | 2015-03-09 | 2016-03-07 | Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20180042929A1 (es) |
| EP (1) | EP3268005A1 (es) |
| JP (1) | JP2018512403A (es) |
| KR (1) | KR20180013850A (es) |
| CN (1) | CN107683138A (es) |
| AU (1) | AU2016231260A1 (es) |
| BR (1) | BR112017019190A2 (es) |
| CA (1) | CA2978807A1 (es) |
| CL (1) | CL2017002284A1 (es) |
| EA (1) | EA201791975A1 (es) |
| HK (1) | HK1250645A1 (es) |
| IL (1) | IL254168A0 (es) |
| MA (1) | MA43840A (es) |
| MX (1) | MX2017011607A (es) |
| PH (1) | PH12017501644A1 (es) |
| SG (1) | SG11201707239WA (es) |
| TN (1) | TN2017000385A1 (es) |
| WO (1) | WO2016142313A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| UA119537C2 (uk) | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| CA2978830A1 (en) | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| EP3645005A1 (en) * | 2017-06-28 | 2020-05-06 | Bayer Consumer Care AG | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| CN111500587A (zh) * | 2020-04-15 | 2020-08-07 | 湖南省科域生物医药科技有限公司 | Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒 |
| EP4143569A4 (en) * | 2020-05-01 | 2024-05-29 | Mayo Foundation for Medical Education and Research | Methods and materials for treating endometrial cancer |
| WO2022140467A1 (en) * | 2020-12-21 | 2022-06-30 | Samson Pharma, Llc | Topical compositions and methods of treating skin diseases and conditions with such compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ565748A (en) * | 2005-09-07 | 2011-04-29 | Serono Lab | PI3K inhibitors for the treatment of endometriosis |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| PE20130191A1 (es) * | 2010-04-16 | 2013-02-21 | Bayer Ip Gmbh | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| WO2014191938A1 (en) * | 2013-05-31 | 2014-12-04 | Novartis Ag | Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer |
-
2016
- 2016-03-07 JP JP2017548211A patent/JP2018512403A/ja not_active Withdrawn
- 2016-03-07 MA MA043840A patent/MA43840A/fr unknown
- 2016-03-07 US US15/557,036 patent/US20180042929A1/en not_active Abandoned
- 2016-03-07 EP EP16708402.9A patent/EP3268005A1/en not_active Withdrawn
- 2016-03-07 CN CN201680022080.8A patent/CN107683138A/zh active Pending
- 2016-03-07 CA CA2978807A patent/CA2978807A1/en not_active Abandoned
- 2016-03-07 BR BR112017019190A patent/BR112017019190A2/pt not_active Application Discontinuation
- 2016-03-07 WO PCT/EP2016/054728 patent/WO2016142313A1/en not_active Ceased
- 2016-03-07 MX MX2017011607A patent/MX2017011607A/es unknown
- 2016-03-07 AU AU2016231260A patent/AU2016231260A1/en not_active Abandoned
- 2016-03-07 SG SG11201707239WA patent/SG11201707239WA/en unknown
- 2016-03-07 HK HK18110118.6A patent/HK1250645A1/zh unknown
- 2016-03-07 KR KR1020177027607A patent/KR20180013850A/ko not_active Withdrawn
- 2016-03-07 EA EA201791975A patent/EA201791975A1/ru unknown
- 2016-03-07 TN TNP/2017/000385A patent/TN2017000385A1/en unknown
-
2017
- 2017-08-27 IL IL254168A patent/IL254168A0/en unknown
- 2017-09-08 PH PH12017501644A patent/PH12017501644A1/en unknown
- 2017-09-08 CL CL2017002284A patent/CL2017002284A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2017000385A1 (en) | 2019-01-16 |
| MA43840A (fr) | 2018-11-21 |
| BR112017019190A2 (pt) | 2018-04-24 |
| CL2017002284A1 (es) | 2018-05-18 |
| EP3268005A1 (en) | 2018-01-17 |
| JP2018512403A (ja) | 2018-05-17 |
| SG11201707239WA (en) | 2017-10-30 |
| CA2978807A1 (en) | 2016-09-15 |
| CN107683138A (zh) | 2018-02-09 |
| EA201791975A1 (ru) | 2018-03-30 |
| HK1250645A1 (zh) | 2019-01-11 |
| PH12017501644A1 (en) | 2018-03-12 |
| AU2016231260A1 (en) | 2017-09-21 |
| WO2016142313A1 (en) | 2016-09-15 |
| US20180042929A1 (en) | 2018-02-15 |
| IL254168A0 (en) | 2017-10-31 |
| KR20180013850A (ko) | 2018-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501644A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| MY169532A (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| EA201791974A1 (ru) | Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин | |
| Versmissen et al. | Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension | |
| GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
| MA34903B1 (fr) | Derives de type azaindazole ou diazaindazole utilises comme medicaments | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| TN2015000452A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas | |
| MY180365A (en) | Markers of tumor cell response to anti-cancer therapy | |
| EA201100426A1 (ru) | Бициклические ингибиторы киназы | |
| ZA202304064B (en) | Quinoline cgas antagonist compounds | |
| SG10201906270VA (en) | Combination therapy comprising a b-raf inhibitor and a second inhibitor | |
| Gettinger et al. | A decade of advances in treatment for advanced non–small cell lung cancer | |
| JP2014533960A5 (es) | ||
| Jiao et al. | Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation | |
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| Nokhostin et al. | The multifaced role and therapeutic regulation of autophagy in ovarian cancer | |
| EP2948137A1 (en) | Methods of treatment of fibrosis and cancers | |
| Bayraktar et al. | Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma | |
| Reichardt | Optimal use of targeted agents for advanced gastrointestinal stromal tumours | |
| Shin et al. | Serum 25-hydroxyvitamin D levels correlate with EGFR mutational status in pulmonary adenocarcinoma | |
| Nyt et al. | Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints | |
| Singh et al. | Renin angiotensin system activity in different cancers: Mechanistic insight and preclinical studies | |
| Mayor | MET inhibitors: translating from bench to bedside | |
| MX2015011833A (es) | Kits y métodos para el tratamiento de cáncer con péptidos de gliadina. |